Sun Pharma Shares Surge 12% Amid Acquisition News, Analysts Predict Further Growth
Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?
Business Standard
Image: Business Standard
Shares of Sun Pharmaceutical Industries (Sun Pharma) rose by 12% over four days, reaching ₹1,807.80 on the National Stock Exchange. This surge follows the announcement of its acquisition of Organon for $11.75 billion, which analysts believe will enhance Sun Pharma's revenue and market presence, especially in women's health and biosimilars.
- 01Sun Pharma's stock increased by 12% in four days, nearing its 52-week high.
- 02The company announced a $11.75 billion acquisition of Organon, enhancing its market position.
- 03Analysts have mixed views, with some upgrading ratings and others remaining cautious.
- 04The acquisition is expected to double revenue to approximately $12 billion.
- 05Challenges include managing debt and ensuring portfolio growth beyond generics.
Advertisement
In-Article Ad
Sun Pharmaceutical Industries (Sun Pharma) saw its share price rise by 12% over four trading days, reaching ₹1,807.80 on the National Stock Exchange (NSE). This increase comes after the company announced a definitive agreement to acquire Organon, a global healthcare company, for $11.75 billion. The acquisition is expected to significantly boost Sun Pharma's revenue, potentially doubling it to around $12 billion. Analysts have varying opinions on the acquisition; while some, like Elara Capital, maintain a 'BUY' rating with a target price of ₹1,968, others, such as ICICI Securities, downgraded their rating to 'HOLD' with a target of ₹1,960. Despite concerns about the $9.5 billion debt raise, analysts believe that the strategic benefits of the acquisition will outweigh the risks, particularly in the women's health and biosimilars markets, which face less competition than traditional generics. The deal is expected to enhance Sun Pharma's market presence, particularly in China and South Korea, while reducing its dependence on the US market.
Advertisement
In-Article Ad
The acquisition is likely to enhance job opportunities and market presence in India, particularly in the healthcare sector.
Advertisement
In-Article Ad
Reader Poll
Do you think Sun Pharma's acquisition of Organon will benefit the company in the long term?
Connecting to poll...
More about Sun Pharmaceutical Industries

Sun Pharma Plans Swift Refinancing of $11.75 Billion Debt Post-Organon Acquisition
Business Standard • Apr 29, 2026
Sun Pharma Acquires Organon for $11.75 Billion: Opportunities and Challenges Ahead
The Economic Times • Apr 28, 2026

Sun Pharma's Acquisition of Organon Boosts Stock Amid Growth Concerns
Business Standard • Apr 27, 2026
Read the original article
Visit the source for the complete story.


